Cough Sound Recordings to Understand COVID-19-like Symptom Progression to Understand COVID-19-like Symptom Progression

Sponsor
ResApp Health Limited (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04989452
Collaborator
(none)
1,500
1
3.7
400.5

Study Details

Study Description

Brief Summary

Decentralized clinical study designed to collect further cough sounds, self-reported symptoms, and medical treatment questionnaires from participants enrolled on the COVID-Cough Study ("Study 1").

The aim of this further data collection study ("Study 2") is to:
  1. develop an understanding of changes in cough sounds associated with COVID-19 and how they alter during the disease;

  2. develop an understanding of other causes of COVID-19-like symptoms and their associated cough sound patterns; and

  3. gain a broader understanding of the clinical outcomes of individuals who present for COVID-19 testing.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Recordings of cough sounds from adults

Detailed Description

This study is designed to be administered in a decentralized manner to collect self-reported COVID-19 symptoms, cough sample recordings and descriptions of recent medical treatment to investigate the following:

  1. Whether patterns unique to COVID-19 disease can be detected in cough sounds collected over time;

  2. The incidence of COVID-19 and other lung diseases within individuals who test negative for COVID-19;

  3. Whether existing machine learning algorithms can detect the presence of disease in the lower respiratory tract in participants; and

  4. Whether distinct cough sound patterns in COVID-19 disease are associated with the requirement of medical treatment for COVID-19 disease. Through the administration of Study 1, a list of potential participants will be created for whom the result of a recent rt-qPCR COVID-19 test is known. Participants have been consented to allow for outreach regarding further studies. Cough samples and answers to medical questions have been collected from these individuals at the time of testing, and the aim of Study 2 is to gather further cough samples and questionnaire answers over a period of 25 days.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Pilot Study for the Collection of Vocalized, Individual Digital Cough Sound Recordings to Understand COVID-19-like Symptom Progression
Actual Study Start Date :
Aug 10, 2021
Anticipated Primary Completion Date :
Nov 2, 2021
Anticipated Study Completion Date :
Dec 2, 2021

Outcome Measures

Primary Outcome Measures

  1. Collection of cough sound audio recordings made using a smartphone, self-reported respiratory symptoms, COVID-19 rt-qPCR result and medical treatment information on 3 occasions (day 1, day 10, day 25). [6 months]

  2. Sensitivity and specificity of using cough sound analysis on longitudinal cough sounds to detect COVID-19 as compared to rt-qPCR test. [10 months]

  3. Sensitivity and specificity of longitudinal cough sounds to detect whether study participants have required recent medical care for COVID-19 related illness. [10 months]

Secondary Outcome Measures

  1. Confusion matrix outputs of cough sound algorithm prediction of COVID-19 severity compared against COVID-19 severity measured by a combination of medical history survey and rt-qPCR test. [10 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • be aged 21 years and older;

  • be a resident of the USA;

  • have a personal (i.e., not shared) iPhone 6s or newer running iOS 14 or later;

  • be able to read and understand English;

  • be able to provide informed consent;

  • be willing to follow study procedures;

  • be able to provide at least 5 coughs (voluntary and/or spontaneous);

  • have enrolled in the COVID-Cough Study and successfully returned an at-home rt-qPCR test to the study partner laboratory

Exclusion Criteria:

Participant has one or more medical contraindication to voluntary cough, including the following:

  • Severe respiratory distress;

  • History of pneumothorax;

  • Eye, chest, or abdominal surgery within 3 months of enrolling for the study; or

  • Hemoptysis (coughing up of blood) within 1 month of enrolling for the study;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Strategy Health LLC New York New York United States 10024

Sponsors and Collaborators

  • ResApp Health Limited

Investigators

  • Principal Investigator: Shrawan Patel, MBBS,BSc, Strategy Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ResApp Health Limited
ClinicalTrials.gov Identifier:
NCT04989452
Other Study ID Numbers:
  • 21002
First Posted:
Aug 4, 2021
Last Update Posted:
Aug 24, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2021